# An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

> **NCT02872285** · PHASE2 · COMPLETED · sponsor: **Lycera Corp.** · enrollment: 33 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Drug: LYC-30937-EC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02872285
- **Lead sponsor:** Lycera Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-05
- **Primary completion:** 2017-06-22
- **Final completion:** 2017-06-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02872285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02872285, "An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02872285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*